-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Cormedix, Raises Price Target to $15

Benzinga·05/07/2025 11:13:39
Listen to the news
Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and raises the price target from $12 to $15.